21 results
8-K
EX-99.2
ME
23andMe Holding Co - Ordinary Shares
8 Jan 24
Regulation FD Disclosure
7:45am
in the clinic yet Autoimmunity Immune Polarization Atopy Inflammation Chronic Infection Tissue Repair “I” Immune phenotypes Cases Vitiligo 60,701
8-K
EX-99.1
ME
23andMe Holding Co - Ordinary Shares
8 Jan 24
Regulation FD Disclosure
7:45am
injuries) Stroke (cerebrovascular diseases) Chronic lower respiratory diseases Alzheimer’s disease Diabetes Chronic liver disease and cirrhosis Nephritis
8-K
EX-99.1
ME
23andMe Holding Co - Ordinary Shares
17 Apr 23
Regulation FD Disclosure
4:10pm
8,000+ Customers with a tested BRCA1 / BRCA2 variant 18,000+ Customers with an increased risk for Chronic Kidney Disease90% of 23andMe+ members receive
8-K
EX-99.1
ME
23andMe Holding Co - Ordinary Shares
9 Nov 22
Investor Presentation November 2022
7:30am
with Hypercholesterolemia (FH) variants 8,000+ Customers with a tested BRCA1 / BRCA2 variant 18,000+ Customers with an increased risk for Chronic Kidney
POS AM
l4apd9s
3 Nov 22
Prospectus update (post-effective amendment)
4:14pm
8-K
EX-99.1
el3fnrd
18 Aug 22
Investor Presentation August 2022
4:06pm
DEF 14A
rgpjcn2ua g2
15 Jul 22
Definitive proxy
8:05am
424B3
1nxvyzll
27 May 22
Prospectus supplement
4:52pm
8-K
EX-99.1
krproo0znbn3 gco0
23 Feb 22
Regulation FD Disclosure
9:31am
8-K
EX-99.1
01p2ld04hp w2rttq
18 Jan 22
Regulation FD Disclosure
8:15am
8-K
EX-99.1
tj8p1x
10 Sep 21
Regulation FD Disclosure
7:02am
424B3
hrenbg9
23 Jul 21
Prospectus supplement
4:31pm
425
2y1 uzl0nl06dm
7 May 21
Business combination disclosure
12:15pm
425
kgqwat9zba
5 Apr 21
Business combination disclosure
4:58pm
8-K
EX-99.3
ru3jmkisa
4 Feb 21
Entry into a Material Definitive Agreement
8:45am
8-K
EX-99.2
o5i ifunx
4 Feb 21
Entry into a Material Definitive Agreement
8:45am
425
EX-99.2
rvgjpcekfa gnm
4 Feb 21
Business combination disclosure
8:43am